Title: Enoxaparin
Literature References: Low molecular weight fragment of heparin, q.v., prepd by depolymerization of a benzylic ester of porcine mucosal heparin. The majority of components present a 2-O-sulfo-a-L-threo-hex-4-enopyranuronic acid structure at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine structure at the reducing end of the chain. Average mol wt ~4500 daltons. Prepn: J. Mardiguian, EP 40144 (1981 to Pharmindustrie), C.A. 96, 218191s (1982). Determn in human plasma: L. Bara et al., Haemostasis 17, 127 (1987). Symposium on pharmacology and clinical efficacy: ibid. 16, 69-188 (1986). Review of pharmacology and use in prevention and treatment of deep venous thrombosis: M. M. Buckley, E. M. Sorkin, Drugs 44, 465-497 (1992); in unstable angina: S. Noble, C. M. Spencer, ibid. 56, 259-272 (1998).
Derivative Type: Sodium salt
Manufacturers' Codes: PK-10169; RP-54563
Trademarks: Clexane (Aventis); Lovenox (Aventis)
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.

Others monographs:
Cottonseed OilHexafluoroacetonePinacolp,α-Dimethylbenzyl Alcohol
Chloral HydrateTitanium TrichlorideCodeine N-OxideLonafarnib
FlurandrenolideTruxillic AcidTrofosfamidePentacene
©2016 DrugLead US FDA&EMEA